Principal Financial Group Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,671,658 shares of the medical equipment provider's stock after buying an additional 34,420 shares during the quarter. Principal Financial Group Inc. owned 0.11% of Boston Scientific worth $159,393,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth about $26,000. Murphy & Mullick Capital Management Corp grew its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares during the period. United Community Bank grew its stake in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the period. Colonial Trust Co SC grew its stake in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares during the period. Finally, Bangor Savings Bank grew its stake in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 142 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.
Boston Scientific Trading Down 1.5%
Shares of NYSE:BSX opened at $55.98 on Wednesday. The stock has a 50 day moving average of $66.69 and a 200 day moving average of $84.28. The company has a market cap of $83.20 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $55.88 and a 12-month high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm's revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.
Analyst Ratings Changes
A number of research firms have issued reports on BSX. The Goldman Sachs Group cut their price target on Boston Scientific from $87.00 to $84.00 and set a "buy" rating for the company in a research note on Wednesday, April 22nd. Argus upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. Canaccord Genuity Group cut their price target on Boston Scientific from $109.00 to $71.00 and set a "buy" rating for the company in a research note on Thursday, April 23rd. Wall Street Zen downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. Finally, Citigroup cut their price target on Boston Scientific from $94.00 to $87.00 and set a "buy" rating for the company in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.91.
Get Our Latest Stock Analysis on BSX
About Boston Scientific
(
Free Report)
Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
